![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TGFBR1 |
Gene summary for TGFBR1 |
![]() |
Gene information | Species | Human | Gene symbol | TGFBR1 | Gene ID | 7046 |
Gene name | transforming growth factor beta receptor 1 | |
Gene Alias | AAT5 | |
Cytomap | 9q22.33 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DXN7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7046 | TGFBR1 | LZE24T | Human | Esophagus | ESCC | 4.74e-08 | 1.77e-01 | 0.0596 |
7046 | TGFBR1 | LZE6T | Human | Esophagus | ESCC | 1.21e-02 | 4.88e-02 | 0.0845 |
7046 | TGFBR1 | P2T-E | Human | Esophagus | ESCC | 1.52e-16 | 1.90e-01 | 0.1177 |
7046 | TGFBR1 | P4T-E | Human | Esophagus | ESCC | 9.11e-08 | 1.85e-01 | 0.1323 |
7046 | TGFBR1 | P5T-E | Human | Esophagus | ESCC | 2.03e-02 | -1.02e-01 | 0.1327 |
7046 | TGFBR1 | P8T-E | Human | Esophagus | ESCC | 1.88e-08 | -4.69e-02 | 0.0889 |
7046 | TGFBR1 | P9T-E | Human | Esophagus | ESCC | 2.58e-06 | 5.10e-02 | 0.1131 |
7046 | TGFBR1 | P10T-E | Human | Esophagus | ESCC | 6.54e-07 | -6.99e-02 | 0.116 |
7046 | TGFBR1 | P11T-E | Human | Esophagus | ESCC | 1.55e-06 | 3.48e-01 | 0.1426 |
7046 | TGFBR1 | P12T-E | Human | Esophagus | ESCC | 2.28e-12 | 1.29e-01 | 0.1122 |
7046 | TGFBR1 | P15T-E | Human | Esophagus | ESCC | 7.77e-03 | -2.72e-02 | 0.1149 |
7046 | TGFBR1 | P16T-E | Human | Esophagus | ESCC | 2.12e-10 | -1.11e-01 | 0.1153 |
7046 | TGFBR1 | P20T-E | Human | Esophagus | ESCC | 1.69e-06 | -2.44e-02 | 0.1124 |
7046 | TGFBR1 | P21T-E | Human | Esophagus | ESCC | 7.04e-29 | 5.00e-01 | 0.1617 |
7046 | TGFBR1 | P22T-E | Human | Esophagus | ESCC | 6.89e-08 | -8.27e-02 | 0.1236 |
7046 | TGFBR1 | P23T-E | Human | Esophagus | ESCC | 3.53e-06 | -9.41e-03 | 0.108 |
7046 | TGFBR1 | P24T-E | Human | Esophagus | ESCC | 1.29e-09 | 4.93e-02 | 0.1287 |
7046 | TGFBR1 | P26T-E | Human | Esophagus | ESCC | 1.16e-13 | 9.29e-04 | 0.1276 |
7046 | TGFBR1 | P27T-E | Human | Esophagus | ESCC | 4.33e-17 | -5.84e-02 | 0.1055 |
7046 | TGFBR1 | P28T-E | Human | Esophagus | ESCC | 1.23e-16 | 2.34e-01 | 0.1149 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19048882 | Thyroid | ATC | cranial skeletal system development | 35/6293 | 68/18723 | 1.76e-03 | 8.71e-03 | 35 |
GO:00600211 | Thyroid | ATC | roof of mouth development | 42/6293 | 85/18723 | 1.83e-03 | 9.02e-03 | 42 |
GO:00608401 | Thyroid | ATC | artery development | 48/6293 | 100/18723 | 1.97e-03 | 9.52e-03 | 48 |
GO:0003197 | Thyroid | ATC | endocardial cushion development | 25/6293 | 45/18723 | 2.00e-03 | 9.59e-03 | 25 |
GO:0003203 | Thyroid | ATC | endocardial cushion morphogenesis | 21/6293 | 36/18723 | 2.01e-03 | 9.59e-03 | 21 |
GO:003030719 | Thyroid | ATC | positive regulation of cell growth | 74/6293 | 166/18723 | 2.06e-03 | 9.73e-03 | 74 |
GO:00485688 | Thyroid | ATC | embryonic organ development | 172/6293 | 427/18723 | 2.08e-03 | 9.84e-03 | 172 |
GO:004863815 | Thyroid | ATC | regulation of developmental growth | 136/6293 | 330/18723 | 2.17e-03 | 1.02e-02 | 136 |
GO:00451374 | Thyroid | ATC | development of primary sexual characteristics | 97/6293 | 227/18723 | 2.47e-03 | 1.14e-02 | 97 |
GO:0050673111 | Thyroid | ATC | epithelial cell proliferation | 174/6293 | 437/18723 | 3.49e-03 | 1.55e-02 | 174 |
GO:012019318 | Thyroid | ATC | tight junction organization | 39/6293 | 80/18723 | 3.55e-03 | 1.57e-02 | 39 |
GO:00352654 | Thyroid | ATC | organ growth | 77/6293 | 178/18723 | 4.45e-03 | 1.85e-02 | 77 |
GO:00488441 | Thyroid | ATC | artery morphogenesis | 36/6293 | 74/18723 | 5.19e-03 | 2.12e-02 | 36 |
GO:0003272 | Thyroid | ATC | endocardial cushion formation | 16/6293 | 27/18723 | 5.50e-03 | 2.24e-02 | 16 |
GO:00512163 | Thyroid | ATC | cartilage development | 81/6293 | 190/18723 | 5.70e-03 | 2.30e-02 | 81 |
GO:00487011 | Thyroid | ATC | embryonic cranial skeleton morphogenesis | 24/6293 | 46/18723 | 7.13e-03 | 2.82e-02 | 24 |
GO:0060976 | Thyroid | ATC | coronary vasculature development | 24/6293 | 46/18723 | 7.13e-03 | 2.82e-02 | 24 |
GO:01501462 | Thyroid | ATC | cell junction disassembly | 13/6293 | 21/18723 | 7.34e-03 | 2.87e-02 | 13 |
GO:0050678110 | Thyroid | ATC | regulation of epithelial cell proliferation | 151/6293 | 381/18723 | 7.47e-03 | 2.92e-02 | 151 |
GO:004592720 | Thyroid | ATC | positive regulation of growth | 106/6293 | 259/18723 | 7.90e-03 | 3.06e-02 | 106 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa049268 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa051425 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
hsa046599 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | ADJ |
TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Breast | ADJ |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | DCIS |
TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Breast | DCIS |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | IDC |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Cervix | CC |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | CRC |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | MSI-H |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | SER |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Endometrium | ADJ |
TGFB2 | TGFbR1_R2 | TGFB2_TGFBR1_TGFBR2 | TGFb | Endometrium | ADJ |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Endometrium | AEH |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Esophagus | ESCC |
TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Esophagus | ESCC |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | HNSCC | ADJ |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | HNSCC | OSCC |
TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | HNSCC | OSCC |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | HNSCC | Precancer |
TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | HNSCC | Precancer |
TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Liver | HCC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGFBR1 | SNV | Missense_Mutation | c.1210N>T | p.Asp404Tyr | p.D404Y | P36897 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TGFBR1 | SNV | Missense_Mutation | c.695N>T | p.Glu232Val | p.E232V | P36897 | protein_coding | deleterious(0) | benign(0.251) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
TGFBR1 | SNV | Missense_Mutation | c.239G>A | p.Arg80Gln | p.R80Q | P36897 | protein_coding | tolerated(0.49) | benign(0.149) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD | |
TGFBR1 | SNV | Missense_Mutation | c.1200N>G | p.Phe400Leu | p.F400L | P36897 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
TGFBR1 | SNV | Missense_Mutation | c.559N>T | p.Asp187Tyr | p.D187Y | P36897 | protein_coding | tolerated(0.05) | probably_damaging(0.998) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
TGFBR1 | insertion | In_Frame_Ins | novel | c.1379_1380insTCCTTGTTCCTTCTTACTTCTTCATAGTTGTCTTTGTTTTCT | p.Asn460_Arg461insProCysSerPheLeuLeuLeuHisSerCysLeuCysPheLeu | p.N460_R461insPCSFLLLHSCLCFL | P36897 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TGFBR1 | insertion | Frame_Shift_Ins | novel | c.434_435insTACTC | p.Met146ThrfsTer4 | p.M146Tfs*4 | P36897 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
TGFBR1 | insertion | Nonsense_Mutation | novel | c.656_657insAGGGAAATGAATGAC | p.Arg219_Phe220insGlyLysTerMetThr | p.R219_F220insGK*MT | P36897 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
TGFBR1 | insertion | Frame_Shift_Ins | novel | c.434_435insTACTC | p.Met146ThrfsTer4 | p.M146Tfs*4 | P36897 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TGFBR1 | SNV | Missense_Mutation | novel | c.1465N>A | p.Ala489Thr | p.A489T | P36897 | protein_coding | deleterious(0.03) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 249565800 | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | LY2157299 | |||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | Metelimumab | METELIMUMAB | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 252166689 | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | LY-2382770 | LY-2382770 | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 178102671 | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 223366128 | GALUNISERTIB | |
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 249565874 | ||
7046 | TGFBR1 | DRUGGABLE GENOME, ENZYME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 249565787 | VACTOSERTIB |
Page: 1 2 3 |